Nov 4, 9:18 AM ET
Labcorp said on November 4, 2026 that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10, 2026. A live audio webcast will be available on the company's investor relations website and archived for 180 days, so shareholders can access the remarks. The filing is an administrative disclosure and includes no financial results.
- Fireside chat with CFO Julia Wang on November 10, 2026 at 8:45 a.m. ET
- Live audio webcast at ir.labcorp.com, archived for replay for 180 days
- Press release dated November 4, 2026 furnished as Exhibit 99.1
Read the filing on SEC.gov ↗
Oct 28, 6:57 AM ET
Labcorp reported third-quarter 2026 revenue of $3.81 billion, up 6.9% from a year earlier, and adjusted EPS of $4.78, up 14.5%. Diluted EPS rose 3.3% to $3.22, and the company raised its full-year 2026 revenue growth and adjusted EPS guidance. For shareholders, the headline measures improved and the higher outlook is the most significant change in the release.
- Q3 2026 revenue was $3.81 billion versus $3.56 billion, up 6.9%; organic growth was 5.5%.
- Diluted EPS was $3.22 versus $3.12, up 3.3%; adjusted EPS was $4.78 versus $4.18, up 14.5%.
- Full-year 2026 adjusted EPS guidance was raised to $18.30 to $18.70 from $18.10 to $18.55; enterprise revenue growth guidance was raised to 5.9% to 6.7%.
- Three acquisition agreements were signed after the quarter ended, including Millennium Health and the Myriad Genetics Prenatal Health business, subject to regulatory approvals.
Read the filing on SEC.gov ↗
Oct 21, 6:51 AM ET
Labcorp's Board of Directors declared a cash dividend of $0.72 per share of common stock, announced October 21, 2026. The dividend is payable December 11, 2026, to holders of record at the close of business on November 24, 2026. The filing contains no earnings, guidance, or other financial results.
- Cash dividend of $0.72 per share of common stock declared October 21, 2026
- Payable December 11, 2026
- Record date is the close of business on November 24, 2026
Read the filing on SEC.gov ↗
Aug 14, 8:55 AM ET
Labcorp said executive Megan D. Bailey will resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Brian J. Caveney, M.D., currently President of Early Development Research Laboratories and Chief Medical and Scientific Officer, will take a broader role effective September 1, 2026, overseeing Biopharma Laboratory Services along with the Early Development Research Laboratories and Central Laboratories businesses.
- Megan D. Bailey notified the company of her resignation on August 11, 2026, effective September 4, 2026
- Brian J. Caveney, M.D., takes on expanded role effective September 1, 2026
- Caveney's new title: EVP and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer
- The filing does not state a replacement for Bailey's former role or any financial terms
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
